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Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL).
Objective: To evaluate the eﬀectiveness of topical 25% podophyllin solution in treatment of CL.
Patients and methods: Sixty-ﬁve patients with acute CL enrolled in this study, which was done in the Department of Dermatology,
Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions
ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was conﬁrmed by biopsy
and smear. Lesions were divided into two groups with matching of type and size of lesions
Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions.
Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks.
Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single
lesion while 37(59.677%) patients had multiple lesions.
Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions.
Group B: no lesion was cured.
Conclusions: Topical 25% podophyllin is a new eﬀective topical therapy for CL, with few side eﬀects.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cutaneous leishmaniasis (CL) is a parasitic disease
caused by several species of the genus Leishmania . It is
an endemic disease in Iraq and other countries in Middle
East, with ﬂuctuation in their frequency, sometime
reaching an epidemic state (Sharquie et al., 2001; Desjeux,
1992; Neouimine, 1996). Although, CL is self healing dis-
ease but spontaneous cure may take several months or even
years (Sharquie et al., 2001; Harmay, 1986; Sharquie and
Al-Talib, 1988) and can produce a large number of lesions
(sometimes up to 200) causing serious disability invariably
leaving the patient permanently scared, a stigma whichbehalf of King Saud University.
commons.org/licenses/by-nc-nd/4.0/).
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1988; WHO, 2001). Several topical therapies had been
tested and found to be eﬀective including intralesionally
injected pentavalent antimony compounds (Sharquie and
Al-Talib, 1988; WHO, 1984) hypertonic sodium chloride
(Sharquie, 1995; Sharquie et al., 1994) zinc sulfate
(Sharquie, 1995; Sharquie and Al-Azzawi, 1996) and elec-
trotherapy (Sharquie et al., 1998) as well as topically
applied paramomycin (El-On et al., 1985). The current
recommended systemic treatment which has been in use
since the 1950s is parentally administered pentavalent anti-
mony compounds (Desjeux, 1992; Neouimine, 1996; WHO,
1984). Although eﬀective, these can only be administered
parentally, are expensive and may cause serious side-eﬀects
(Desjeux, 1992; Neouimine, 1996).
Podophyllin is an alcoholic plant extract obtained from
dried rhizomes of common plants called emodi (Indian
podophyllum) or podophyllum peltatum (May apple or
mandrake) which belongs to Berberidaceae (barberry)
family (Martin et al., 2004). Since the 1940s, it has been used
topically for treatment of various skin lesions, especially for
warts, molluscum contagiosum (Ahmed et al., 2008) and as
an anti-neoplastic agents (Martin et al., 2004) where it had
been used in the treatment of keratoacanthoma (Habif,
2004), oral hairy leukoplakia (James et al., 2006), multiple,
superﬁcial of inﬁltrating basal cell epithelioma, squamous
cell epithelioma, seborrheic keratosis, and actinic keratosis
(United State Pharmacopeia Committees, 2004) also it has
antifungal activity (Rahman et al., 1995).
Podophyllin resin is an anti-mitotic and caustic agent
with anti-viral activity (United State Pharmacopeia
Committees, 2004; Reynolds, 1993; Sackett, 1993). The
possible mechanism of action includes (Oslen and Dart,
2004; Canel, 2000; Moore and Strober, 2008): arresting cel-
lular mitosis in metaphase, this is done by the reversal bind
to tubuline which is the protein subunit of the spindle
microtubules at a site that is the same of overlaps with
the colchicines binding site thereby preventing polymeriza-
tion of tubuline into microtubules. So it will disturb the cel-
lular cytoskeleton. Also it blocks oxidation enzymes in
tricarboxylic acid cycle, so it will interfere with nutrition
of cells. In addition, it inhibits the axonal transport, pro-
tein, RNA, DNA synthesis and mitochondrial activity with
the reduction of cytochrome oxidase activity.
Therefore the aim of the present study was to evaluate
the eﬀectiveness of topical 25% podophyllin solution in
treatment of CL.
2. Patients and methods
This single, blinded, therapeutic, controlled trial was
carried out in the Department of Dermatology, Baghdad
Teaching Hospital, Baghdad, Iraq, during the period from
January 2008 to April 2009.
A total of 65 patients with typical acute CL enrolled in
this study; 35(53.8%) were females and 30(46.2%) were
males and their ages range from 3 to 50 years with amean ± SD of 22.89 ± 14.82 years. The total number of
lesions was 124; 83(66.93%) ulcerated and 41(33.06%) dry
and the size of lesions ranged from 0.5 to 3 cm in diameter
with a mean ± SD of 1.75 ± 1.81 cm. The duration of
lesions ranged from 3 to 12 weeks with a mean ± SD of
6.84 ± 2.902 weeks.
Full history and examination were performed including:
age, sex, residence, job, duration, type, site.
Any patients with the following criteria were excluded
from this study: Pregnancy (United State Pharmacopeia
Committees, 2004), chronic diseases like diabetes mellitus,
peripheral neuropathy, poor peripheral circulation,
immune compromised patients and other severe illnesses
and patients on prolonged corticosteroid therapy
(Podophyllin in benzoin tincture, 1999), lesion with surface
area more than 10 cm2 or lesions close to eyes(United State
Pharmacopeia Committees, 2004). Also, patients who
received anti-leishmanial treatment either local or systemic
and lesions of more than 12 weeks duration to exclude the
possibility of self healing during follow-up period
(Sharquie et al., 2001). Patients with re-infestation were
also excluded.
Formal consent was taken from each patient after full
interrogation and explanation to each patient about the
nature of the disease, course, treatment modalities and
complications, follow up, prognosis and the need for pre
and post treatment photographs.
Also the ethical approval was performed by the
Scientiﬁc Committee of the Scientiﬁc Council of
Dermatology and Venereology-Iraqi Board for Medical
Specializations. All the patients had been diagnosed by his-
tory and clinical examination, and conﬁrmed by biopsy
and smear.
In many patients, some lesions, which were located in
the covered area, were untreated and left as a control after
obtaining the consent of the patient. This is also beneﬁcial
to the patient as it gives long lasting immunity (WHO,
1984).
Regarding the therapy, lesions had been divided into
two groups with matching of type and size of lesions.
Group A: treated with 25% topical podophyllin solution
in tincture benzoin. It was prepared by dissolving 25 g of
podophyllin resin powder, purchased from Merck
Company, Germany, in 100 ml of tincture benzoin. This
solution was applied with cotton-tipped applicator. The
amount of solution that was used in each session did not
exceed 0.5 ml and the surface area treated did not exceed
10 cm2, in order to minimize the local and systemic side
eﬀects of the drug. The podophyllin solution was allowed
to dry in approximately 2 min and patients were instructed
to wash oﬀ it after 6–8 h. The solution was applied once
weekly for maximum 6 weeks.
Group B: the lesions in this group received no treatment
and left as a control group.
Follow-up of patients in two groups was every 2 weeks
for 8 weeks and on each visit; all lesions were re-assessed
to record the degree of the response and any local and
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marking the indurations and measuring its diameter with
a caliber and a photo was taken in the same place, light
and distance by using SONY Cybershot camera W120
super steady 7.5 Mega pixel.
The response to therapy was graded according to the
scale of Sharquie et al. Sharquie and Al-Talib (1988):
 Slight: decrease in erythema and edema of the
lesion.
 Mild: reduction in the size of the lesion up to 30%.
 Moderate: reduction in the size of the lesion of
>30–60%.
 Marked: reduction in the size of the lesion >60%
with parasites not detected in the aﬀected area by
smear and/or culture.
 Total clearance of the lesion with parasites not
detected in the aﬀected area by smear and/or
culture.
Both marked improvement and total clearance were
considered as a cure.3. Results
A total of 62 out of 65 patients with acute CL completed
the study. Three patients with 4 lesions were lost forTable 1
Showing the grade of response in treated lesions of cutaneous leishmania
with 25% podophyllin solution.
Grade of response No. of lesions % No. of sessions
Slight 3 5 6
Mild 2 3.33 6
Moderate 4 6.667 6




Figure 1. (A) Thirty-one year old lady with CL before treatment with 25% pod
with 25% podophyllin solution.unknown reason and regarded as default. Thus, the total
number of lesions that followed up became 120 lesions
including 79(65.84%) ulcerated and 41(34.16%) dry, sta-
tistically, there was no signiﬁcant diﬀerence between the
treated and controlled group, regarding the number of
the ulcerated and the dry lesions in each group, where,
v2 = 0.3375 and P value = 0.5613.
In Group A: 51(85%) lesions out of 60 lesions had been
cured with number of sessions ranging from 3–6 with a
mean ± SD of 5.137 ± 0.9385 sessions (Table 1 and
Figs. 1 and 2). It’s worthy to be mentioned that
36(94.73%) ulcerated lesions out of total 38 ulcerated
lesions had cure with 3–6 sessions of therapy, and
15(68.18%) dry lesions out of total 22 dry lesions had com-
plete cure with 3–6 sessions of therapy, where v2 = 5.764
and P-value < 0.0164 (Table 2).
In Group B: no lesion out of 60 lesions showed any sign
of healing till the end of follow up and some of them were
increased in size.
Regarding side eﬀects, no serious local or systemic side
eﬀects occurred. Mild burning sensation occurring in 10%
patients was tolerable; localized edema at the site of lesions
occurred in 70% of treated lesions that subsided within
2–3 days. In all cured lesions, there was no visible scarring
at the site of lesions, but post-inﬂammatory hyper
pigmentation was noted in all treated lesions.
4. Discussion
Cutaneous leishmania is a self-healing disease, but
spontaneous cure may take several months or even years.
Therapy aims to shorten the duration of lesions and
prevent scarring (Sharquie et al., 2001). Several topical
therapies had been tested and found to be eﬀective includ-
ing: Intralesionally injected Sb+5compounds (Sharquie
and Al-Talib, 1988), 7% hypertonic sodium chloride
(Sharquie et al., 1994), 2% zinc sulfate solution (Sharquie
and Al-Azzawi, 1996), topically applied paramycin
(Bryceson, 1987) and cryotherapy (Zarcarian, 1985).ophyllin solution. (B) The same lady with CL after 6 sessions of treatment
Figure 2. (A): Five year old child with CL before treatment with 25% podophyllin solution. (B): The same patient after 6 sessions of treatment.
Table 2
Showing the diﬀerence in response between the ulcerated and the dry
lesion in each grade of response.
Grade of response Ulcerated lesions Dry lesion Total
Slight 1 (2.63%) 2 (9.09%) 3
Mild 0 2 (9.09%) 2
Moderate 1 (2.63%) 3 (13.63%) 4
Cure 36 (94.73%) 15 (68.18%) 51
Total 38 22 60
v2 = 5.764 and P value < 0.0164.
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lesions (Vegas-lopez and Hay, 2004), to increase the con-
centration of the drug at the lesional site, and then to
increase its eﬀectiveness also to reduce the cost of therapy
and to avoid the side eﬀects of systemic drugs (Sharquie
et al., 1994). Systemic treatment for CL is often advised
when there are numerous and/or big lesions that cannot
be locally inﬁltrated (WHO, 1984).
The current recommended systemic treatment, which
has been in use since the 1950s, is parentally administered
sodium stibogluconate antimony compounds. Although,
it is eﬀective they are expensive and may cause serious side
eﬀects (Sharquie et al., 2001). Other systemic drugs that
were used in the treatment of CL like oral zinc sulfate
(Sharquie et al., 2001), allopurinol (WHO, 1992), ampho-
tericin B (James et al., 2006), rifampicin (Joshi and
Nambair, 1989), antifungal agent (Berman et al., 1986),
trimethoprim (Turki and Abboud, 1983), levamisole
(Buller, 1978), dapson (Dogra, 1991) and chloroquine
(Bryceson, 1979). Thus, the ideal therapy should be rapidly
eﬀective, easily administered, non costly, available at all
times, and should have no important side eﬀects
(Sharquie et al., 1994).
In the present study, 25% podophyllin solution used
topically in treatment of CL gave encouraging results with
85% cure rate in comparison with the controlled group
which revealed no signs of healing.
The cure rate (85%) in the present study is higher than
reported in topical application of paromomycin which
was reported up to 80% twice daily applications of the15% paromomycin ointment on CL in the 4 weeks regimen
(El-saﬁ et al., 1990; Faghihi and Tavakoli-kia, 2003), also
severe inﬂammatory reaction with application of the 15%
paromomycin ointment had been reported (Bryceson,
1987). In addition, this drug is costly and unavailable
and their biochemical mechanisms are totally unknown
(Berman, 1991).
Also, podophyllin gave high cure rate in comparison
with use of topical clotrimazole that showed response cure
rate reaching to 15.7% (Harmay, 1986; Larbi et al., 1995).
Intralesional sodium stibogluconate, 7% hypertonic
sodium chloride, 2% zinc sulfate solution had been used
in treatment of acute CL and gave high cure rate with
30–40 days, which are comparable with podophyllin which
is given every 7 days, but these therapies need local injec-
tions which are painful that need mixing with xylocaine
(Sharquie and Al-Talib, 1988; Sharquie et al., 1994;
Sharquie and Al-Azzawi, 1996).
In addition, 25% podophyllin gave high cure rate in
comparison with combination of topical 5% imiquimod
and intralesionally meglumine antimoniate which revealed
37% cure rate (Khatami et al., 2007).
However, cryotherapy had been also used in the treat-
ment of CL, but with a cure rate reaching to 30%
(Bassiony et al., 1982) and with many side eﬀects espe-
cially ugly scarring and permanent hypopigmentation, in
addition to that, it was a painful method (Zarcarian,
1985). So 25% podophyllin gave a high cure rate than
the cryotherapy method and cosmetically was more
accepted.
This study revealed that the ulcerated lesions had a bet-
ter response than dry lesions for this therapy and there was
a statistically signiﬁcant diﬀerence.
No important local or systemic side eﬀects occurred fol-
lowing topical use of podophyllin apart from mild burning
sensation that occurred in 10% of patients but was tolera-
ble. All cured lesions healed with no or minimum scar and
these results are similar to that reported in other modalities
of treatment of CL.
The possible mechanism of action of podophyllin as
antileishmanial drug could not be certain but the well
known actions of podophyllin on cells could be applied
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cellular mitosis in metaphase, blocking oxidation enzymes
in tricarboxylic acid cycle, inhibiting axonal transport,
protein, RNA, DNA synthesis and also inhibit of
mitochondrial activity(Oslen and Dart, 2004; Canel, 2000;
Vegas-lopez and Hay, 2004). All these mechanisms could
lead to death of the parasite, followed by cure of the lesion.
In conclusion, topical 25% podophyllin solution is an
eﬀective new topical therapy of CL. It is a non costly, avail-
able and painless method of therapy especially suitable for
children with few side eﬀects. Further in vitro studies and
more clinical evaluations are recommended.
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